CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 203 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is 1.16 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,352,887 | +4296.3% | 33,086 | +4444.8% | 0.02% | +2200.0% |
Q1 2024 | $30,773 | -86.8% | 728 | -86.7% | 0.00% | -66.7% |
Q4 2023 | $232,395 | +662.1% | 5,481 | +292.3% | 0.00% | +200.0% |
Q3 2023 | $30,496 | -77.5% | 1,397 | -67.2% | 0.00% | -80.0% |
Q2 2023 | $135,489 | +208344.6% | 4,262 | +59.4% | 0.01% | +150.0% |
Q1 2023 | $65 | -44.9% | 2,674 | -28.6% | 0.00% | -60.0% |
Q4 2022 | $118 | -99.9% | 3,747 | -19.4% | 0.01% | +150.0% |
Q3 2022 | $131,000 | -18.6% | 4,649 | -23.6% | 0.00% | -50.0% |
Q2 2022 | $161,000 | -16.1% | 6,084 | +10.5% | 0.00% | +100.0% |
Q1 2022 | $192,000 | +1.6% | 5,506 | -5.6% | 0.00% | -33.3% |
Q4 2021 | $189,000 | -47.1% | 5,830 | -51.8% | 0.00% | -66.7% |
Q3 2021 | $357,000 | +792.5% | 12,093 | +678.2% | 0.01% | +800.0% |
Q2 2021 | $40,000 | +400.0% | 1,554 | +155.2% | 0.00% | – |
Q1 2021 | $8,000 | +300.0% | 609 | +509.0% | 0.00% | – |
Q4 2020 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |